VT-1161: has antifungal activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 77050711 |
| CHEMBL ID | 3311228 |
| CHEBI ID | 188153 |
| SCHEMBL ID | 17113021 |
| MeSH ID | M000607495 |
| Synonym |
|---|
| bdbm50046187 |
| chembl3311228 , |
| 1340593-59-0 |
| vt-1161 |
| oteseconazole |
| CHEBI:188153 |
| (r)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1h-tetrazol-1-yl)-1-(5-(4-(2,2,2-trifluoroethoxy)phenyl)pyridin-2-yl)propan-2-ol |
| VHH774W97N , |
| vivjoa |
| oteseconazole [usan] |
| (alphar)-alpha-(2,4-difluorophenyl)-beta,beta-difluoro-alpha-(1h-tetrazol-1-ylmethyl)-5-[4-(2,2,2-trifluoroethoxy)phenyl]-2-pyridineethanol |
| 2-pyridineethanol, alpha-(2,4-difluorophenyl)-beta,beta-difluoro-alpha-(1h-tetrazol-1-ylmethyl)-5-[4-(2,2,2-trifluoroethoxy)phenyl]-, (alphar)- |
| oteseconazole [inn] |
| oteseconazole [who-dd] |
| oteseconazole, (+)- |
| SCHEMBL17113021 |
| who 10138 |
| 2-pyridineethanol, alpha-(2,4-difluorophenyl)-beta,beta-difluoro-alpha-(1h-tetrazol-1-ylmethyl)-5-(4-(2,2,2-trifluoroethoxy)phenyl)-, (alphar)- |
| unii-vhh774w97n |
| DB13055 |
| (2r)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1h-tetrazol-1-yl)-1-{5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl}propan-2-ol |
| AKOS032946517 |
| (2r)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(tetrazol-1-yl)-1-[5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl]propan-2-ol |
| HY-17643 |
| SB17420 |
| CS-0016914 |
| oteseconazole (usan/inn) |
| D11785 |
| Q27291837 |
| D87154 |
| MS-29755 |
| vt-1161vt-1161 |
| iduyjrxrdspprc-nrfanrhfsa-n |
| oteseconazolum |
| oteseconazol |
| (i+-r)-i+--(2,4-difluorophenyl)-i2,i2-difluoro-i+--(1h-tetrazol-1-ylmethyl)-5-(4-(2,2,2-trifluoroethoxy)phenyl)-2-pyridineethanol |
| 2-pyridineethanol, i+--(2,4-difluorophenyl)-i2,i2-difluoro-i+--(1h-tetrazol-1-ylmethyl)-5-(4-(2,2,2-trifluoroethoxy)phenyl)-, (i+-r)- |
| EX-A8008 |
VT-1161 was shown to be efficacious and safe in the treatment of patients with recurrent vulvovaginal candidiasis. There was no evidence of an adverse effect on liver function or QT intervals.
We evaluated the safety and efficacy of four dosing regimens of orally administered VT-1161 compared with placebo in patients with moderate-to-severe distal and lateral subungual onychomycosis of the toenail. The efficacy profile of VT-1061 was equivalent to those of itraconazole and terbinafine except when each drug was dosed once weekly.
| Class | Description |
|---|---|
| organic molecular entity | Any molecular entity that contains carbon. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 (µMol) | 65.0000 | 0.0001 | 1.7536 | 10.0000 | AID1180169; AID1487215 |
| Cytochrome P450 2C9 | Homo sapiens (human) | IC50 (µMol) | 99.0000 | 0.0000 | 2.8005 | 10.0000 | AID1180177 |
| Cytochrome P450 2C19 | Homo sapiens (human) | IC50 (µMol) | 72.0000 | 0.0000 | 2.3983 | 10.0000 | AID1180178 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Lanosterol 14-alpha demethylase | Candida albicans SC5314 | Kd | 0.0390 | 0.0450 | 0.0970 | 0.1650 | AID1180175 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cytoplasm | Cytochrome P450 3A4 | Homo sapiens (human) |
| endoplasmic reticulum membrane | Cytochrome P450 3A4 | Homo sapiens (human) |
| intracellular membrane-bounded organelle | Cytochrome P450 3A4 | Homo sapiens (human) |
| endoplasmic reticulum membrane | Cytochrome P450 2C9 | Homo sapiens (human) |
| plasma membrane | Cytochrome P450 2C9 | Homo sapiens (human) |
| intracellular membrane-bounded organelle | Cytochrome P450 2C9 | Homo sapiens (human) |
| cytoplasm | Cytochrome P450 2C9 | Homo sapiens (human) |
| intracellular membrane-bounded organelle | Cytochrome P450 2C9 | Homo sapiens (human) |
| endoplasmic reticulum membrane | Cytochrome P450 2C19 | Homo sapiens (human) |
| plasma membrane | Cytochrome P450 2C19 | Homo sapiens (human) |
| intracellular membrane-bounded organelle | Cytochrome P450 2C19 | Homo sapiens (human) |
| intracellular membrane-bounded organelle | Cytochrome P450 2C19 | Homo sapiens (human) |
| cytoplasm | Cytochrome P450 2C19 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1180168 | Antifungal activity against Candida albicans by broth macrodilution method | 2014 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15 | Design and optimization of highly-selective fungal CYP51 inhibitors. |
| AID1180174 | Selectivity index, ratio of IC50 for human hepatocytes CYP3A4 to MIC for Trichophyton rubrum | 2014 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15 | Design and optimization of highly-selective fungal CYP51 inhibitors. |
| AID1180175 | Binding affinity to Candida albicans CYP51 | 2014 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15 | Design and optimization of highly-selective fungal CYP51 inhibitors. |
| AID1180180 | Half life in po dosed human | 2014 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15 | Design and optimization of highly-selective fungal CYP51 inhibitors. |
| AID1180182 | Antifungal activity against Trichophyton mentagrophytes infected in guinea pig dermatophytosis model assessed as mycological efficacy at 10 mg/kg, po administered for 9 days | 2014 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15 | Design and optimization of highly-selective fungal CYP51 inhibitors. |
| AID1180179 | Metabolic stability in human liver microsomes after 2 hrs | 2014 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15 | Design and optimization of highly-selective fungal CYP51 inhibitors. |
| AID1180178 | Inhibition of CYP2C19 (unknown origin) | 2014 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15 | Design and optimization of highly-selective fungal CYP51 inhibitors. |
| AID1180173 | Antifungal activity against Trichophyton rubrum by broth macrodilution method | 2014 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15 | Design and optimization of highly-selective fungal CYP51 inhibitors. |
| AID1180169 | Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method | 2014 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15 | Design and optimization of highly-selective fungal CYP51 inhibitors. |
| AID1180181 | Antifungal activity against Candida albicans infected in mouse candidiasis model assessed as reduction of kidney fungal burden at 10 mg/kg, po | 2014 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15 | Design and optimization of highly-selective fungal CYP51 inhibitors. |
| AID1487214 | Inhibition of CYP51 in Aspergillus fumigatus assessed as inhibition of microbe growth incubated for 48 to 168 hrs by CLSI M27-A3 guideline based method | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15 | Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors. |
| AID1487215 | Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15 | Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors. |
| AID1180176 | Selectivity for yeast CYP51 over human CYP51 | 2014 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15 | Design and optimization of highly-selective fungal CYP51 inhibitors. |
| AID1180177 | Inhibition of CYP2C9 (unknown origin) | 2014 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15 | Design and optimization of highly-selective fungal CYP51 inhibitors. |
| AID1487213 | Inhibition of CYP51 in Candida albicans assessed as inhibition of microbe growth incubated for 48 hrs by CLSI M27-A3 guideline based method | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15 | Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (84.21) | 24.3611 |
| 2020's | 3 (15.79) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (28.83) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (15.79%) | 5.53% |
| Reviews | 1 (5.26%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (78.95%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||